- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- PKD & Rare Kidney Diseases
- Anemia Due To CKD
- CKD & Related Comorbid Conditions
- Kidney Failure & Kidney Replacement Therapies
- Electrolyte Disorders
- NephU Nutrition & The NephChefTM
Did you know that Black patients with autosomal dominant polycystic kidney disease (ADPKD) progress to kidney failure earlier than White patients?1,2 Watch a rebroadcast of this virtual panel discussion, led by nephrology experts, where you can hear about the racial disparities that exist in autosomal dominant polycystic kidney disease (ADPKD), underrepresentation of Black Americans and other people of color in clinical trials, and implicit bias that may impact the treatment of those with ADPKD.
- Yium J et al. J Am Soc Nephrol. 1994;4(9):1670–4.
- Murphy et al. BMC Nephrology (2019) 20:55.
*Drs Neera Dahl, and Loretta Jackson Brown are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Drs Charlotte Jones-Burton & Shirin Sundar are employees of OPDC.
The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry.
Yale School of Medicine*
Dr Neera Dahl is currently a clinician-educator and an Associate Professor at Yale University, School of Medicine, Section of Nephrology. She received her MD and PhD from Tufts University School of Medicine, and completed her residency and fellowship at the Beth Israel Deaconess Medical Center, in Boston, MA. She has been at Yale since 2007. She has been instrumental in developing the Yale Inherited Kidney Disease Clinical Program, and is the principal investigator for several ongoing clinical trials in ADPKD. She maintains an active ADPKD registry and is involved in research exploring the role of inflammation and fibrosis in the progression of ADPKD. She is also the director of the Yale Nephrology Clinical Trials Program and a member of the Scientific Advisory Board for the Polycystic Kidney Disease Foundation.
Otsuka Pharmaceutical Companies (U.S.) & Women of Color in Pharma, Founder*
Dr Jones-Burton is an entrepreneurial pharmaceutical executive, has brought innovation and passion to her diverse roles within the healthcare industry over the last 20+ years as clinical development leader, internal medicine and nephrology physician, academician and change agent. In a top biopharmaceutical company, Dr Jones-Burton leads cross-functional teams to design, implement, and oversee clinical trial studies for innovative medicines. She has also achieved a high level of success as an entrepreneur in direct sales and franchise industries. Dr Jones-Burton excels in building and empowering diverse teams that deliver business results and has received numerous awards, including the new business developer award which was awarded to one of her teams.
Centers for Disease Control*
Dr Brown has been at the Centers for Disease Control and Prevention since 2010. She was initially assigned to the Division of Emergency Operations as a Health Communication Specialist where she conducted outreach and communication activities related to public health emergencies, including pandemic influenza, Ebola, Zika, and Flint water contamination. She contributed to CDC’s global health security agenda by providing emergency risk communication training for international countries, including Tanzania, Sierra Leone, and Malaysia. In her current role, she works as a senior health communication specialist and team lead in the Division of Overdose Prevention where she oversees the development of opioid training materials for healthcare providers, supports states with health communication technical assistance, and develops national campaigns to support drug overdose prevention.
Dr Brown has a combined 22 years of Air Force service, active and reserves. She is a retired Lieutenant Colonel and prior to working at CDC, she was the Chief Nurse Executive for the 94th Aeromedical Staging Squadron at Dobbins Air Reserves Base, GA. A certified nephrology nurse for 25 years, Dr Brown has been a volunteer leader with the American Nephrology Nurses’ Association since 2001 where she served as a Southeast Vice President on the Board of Directors, chaired the leadership development committee, and authored book chapters and journal articles. In 2020 the association recognized Dr Brown with the excellence in nephrology nurse education award and the outstanding volunteer leadership award in 2011.
Dr Brown earned a Bachelor of Science in Nursing from Florida State University and in 2018 received the Florida State University Women of Distinction Inspire Award. She currently serves as chair of the Nole Nurse Alumni Council. She completed a Master’s in Nursing from the University of Southern Mississippi and earned a PhD in nursing from Georgia State University. Since 2013, Dr Brown has served as a member of the Board of Directors for Emory Decatur Hospital in Decatur, GA.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Shirin Sundar, PhD is a Senior Medical Science Liaison at Otsuka, based out of the San Francisco bay area. Dr Sundar earned her Master’s and PhD in Cell and Molecular Biology from Birla Institute of Technology and Science, Pilani, India and the Uniformed Services University, Bethesda, Maryland. She did her post-doctoral training at the Kidney Institute, University of Kansas on elucidating the molecular mechanisms of polycystic kidney disease (PKD), and preclinical drug development for PKD. Prior to joining Otsuka, Dr Sundar held an Assoc. Specialist Scientist position at the University of California San Francisco.
Dr Sundar has presented several abstracts and published peer-reviewed manuscripts in the areas of cellular oxidative stress, innate immune pathways, polycystic kidney disease, and hyponatremia outcomes research.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
September 28 from 6:00 pm to 7:00 pm
September 28 from 9:00 pm to 10:00 pm
October 6 from 12:00 pm to 1:00 pm
- Resource Center
- Presentation Request